ERBB2 and breast carcinoma: Wang et al. reported that some HR + HER2-positive breast cancer cells might be primarily driven by the ER pathway and weakly driven by the HER2 pathway, making them intrinsically less sensitive to anti-HER2 treatment and possible sensitive to endocrine therapy [15].